Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.47 |
| ▸ | PIM1 | P11309 | 5/20 | 0.47 |
| ▸ | GSK3B | P49841 | 5/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 5/20 | 0.45 |
| ▸ | JAK2 | O60674 | 4/20 | 0.45 |
| ▸ | JAK1 | P23458 | 4/20 | 0.45 |
| ▸ | TYK2 | P29597 | 4/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.38 |
| ▸ | RAF1 | P04049 | 2/20 | 0.36 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | SGK1 | O00141 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30161646 | 1.00 | PIK3CD (0.47) | PIK3CDPIM1GSK3BPIK3CAPIK3CB | |
| SCHEMBL30161725 | 0.91 | PIM1 (0.46) | PIK3CDPIM1GSK3BPIK3CAPIK3CB | |
| SCHEMBL20699380 | 0.91 | PIM1 (0.46) | PIK3CDPIM1GSK3BPIK3CAPIK3CB | |
| SCHEMBL20699377 | 0.91 | PIM1 (0.46) | PIK3CDPIM1GSK3BPIK3CAPIK3CB | |
| Trifluoroacetic Acid SCHEMBL29608317 | 0.91 | PIK3CD (0.45) | PIK3CDPIM1GSK3BPIK3CAPIK3CB | |
| Trifluoroacetic Acid SCHEMBL28680413 | 0.91 | PIK3CD (0.45) | PIK3CDPIM1GSK3BPIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL20699394 | 0.90 | PIM1 (0.45) | PIK3CDPIM1GSK3BPIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL20703857 | 0.90 | PIM1 (0.45) | PIK3CDPIM1GSK3BPIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL29606483 | 0.90 | PIM1 (0.45) | PIK3CDPIM1GSK3BPIK3CAPIK3CB | |
| SCHEMBL28696221 | 0.88 | TDO2 (0.36) | PIK3CDPIM1GSK3BPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032646-B | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | 施万生物制药研发IP有限责任公司 | 2023-01-03 | — | — | CN | disclosed |
| US-20220119369-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220119369-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-21 | — | — | US | disclosed |
| CN-113831326-A | Condensed heterocyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2021-12-24 | — | — | CN | disclosed |
| US-10968205-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-10968205-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200216423-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200216423-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-07-09 | — | — | US | disclosed |
| EP-3652169-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2020-05-20 | — | — | EP | disclosed |
| CN-111032646-A | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | 施万生物制药研发IP有限责任公司 | 2020-04-17 | — | — | CN | disclosed |
| US-10538513-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-01-21 | — | — | US | disclosed |
| US-10538513-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-01-21 | — | — | US | disclosed |
| US-20190315724-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315724-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-17 | — | — | US | disclosed |
| US-10392368-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-10392368-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| WO-2019027960-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019027960-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-07 | — | — | WO | disclosed |
| US-20190040043-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-07 | — | — | US | disclosed |
| US-20190040043-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315724-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | PIK3CD 207/4885PIM1 276/4885GSK3B 231/4885 |
| US-10968205-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | JAK3, JAK1, JAK2 | PIK3CD 207/4885PIM1 276/4885GSK3B 231/4885 |
| US-20190040043-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | PIK3CD 207/4885PIM1 276/4885GSK3B 231/4885 |
| US-20220119369-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | PIK3CD 207/4885PIM1 276/4885GSK3B 231/4885 |
| US-10392368-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | JAK3, JAK1, JAK2 | PIK3CD 207/4885PIM1 276/4885GSK3B 231/4885 |
| US-20200216423-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | PIK3CD 207/4885PIM1 276/4885GSK3B 231/4885 |
| US-10538513-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | JAK3, JAK1, JAK2 | PIK3CD 207/4885PIM1 276/4885GSK3B 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.